| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2883065 | The Annals of Thoracic Surgery | 2006 | 7 Pages |
Abstract
Prophylactic DeVega TVA of the donor heart is durable and decreases the incidence of cardiac-related mortality and tricuspid regurgitation after orthotopic heart transplantation. In addition, there is improved protection of renal function. Considering the ease and safety of TVA and its advantages, it should be performed as a routine adjunct to orthotopic heart transplantation.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Valluvan MD, Hyde MD, Paul MD, Satoshi MD, Allen MD, Jaishankar MD, PhD,